Evidence map›Paper›PMID 41127339›Full record

ArticleCancer drug resistance (Alhambra, Calif.)2025

CDK4/6 and BET inhibitors synergistically suppress pancreatic tumor growth and epithelial-to-mesenchymal transition by regulating the GSK3β-mediated Wnt/β-catenin pathway.

Jiangning Gu, Zihao Dai, Tianci Shen, Xiang Chen, Zhuo Yang, Shibo Sun, Dan Chen, Haifeng Luo, Xiuli Wang, Jianqiang Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer drug resistance (Alhambra, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. International journal of molecular sciences · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiangning GuDepartment of Endoscope, General Hospital of Northern Theater Command, Shenyang 110011, Liaoning, China.
Zihao DaiDepartment of Endoscope, General Hospital of Northern Theater Command, Shenyang 110011, Liaoning, China.
Tianci ShenDepartment of Endoscope, General Hospital of Northern Theater Command, Shenyang 110011, Liaoning, China.
Xiang ChenDepartment of Hepatobiliary Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning, China.
Zhuo YangDepartment of Endoscope, General Hospital of Northern Theater Command, Shenyang 110011, Liaoning, China.
Shibo SunSchool of Chemical Engineering, Ocean Technology and Life Science (CEOTLS) & Panjin Institute of Industrial Technology, Dalian University of Technology, Panjin 124221, Liaoning, China.
Dan ChenDepartment of Pathology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning, China.
Haifeng LuoDepartment of Hepatobiliary Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning, China.
Xiuli WangCollege of Basic Medical Sciences, Dalian Medical University, Dalian 116044, Liaoning, China.
Jianqiang XuSchool of Chemical Engineering, Ocean Technology and Life Science (CEOTLS) & Panjin Institute of Industrial Technology, Dalian University of Technology, Panjin 124221, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BET inhibitor JQ1CDK4/6 inhibitor PD-0332991epithelial-to-mesenchymal transitionPancreatic cancerpancreatic ductal adenocarcinomaWnt/β-catenin pathway

Identifiers

PMID41127339
PMCPMC12539222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.